Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing,...
LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...
Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA...
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...
LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor...
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...
LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...